T1	Negation 0 7	Failure
T2	Condition 16 31	fully recovered
R1	Has_negation Arg1:T2 Arg2:T1	
T3	Value 42 76	less than or equal to [<=] Grade 1
T4	Measurement 77 85	toxicity
R2	Has_value Arg1:T4 Arg2:T3	
T5	Procedure 124 136	chemotherapy
T6	Scope 0 31	Failure to have fully recovered
T7	Scope 42 85	less than or equal to [<=] Grade 1 toxicity
R3	Subsumes Arg1:T6 Arg2:T7	
R4	Has_scope Arg1:T5 Arg2:T6	
T8	Procedure 139 152	Major surgery
T9	Temporal 153 185	within 14 days before enrollment
R5	Has_temporal Arg1:T8 Arg2:T9	
T10	Procedure 188 200	Radiotherapy
T11	Temporal 201 233	within 14 days before enrollment
T12	Observation 242 265	involved field is small
A1	Optional T12
T13	Temporal 267 273	7 days
R6	Has_temporal Arg1:T12 Arg2:T13	
*	OR T12 T11
T14	Scope 201 233;242 273	within 14 days before enrollment involved field is small, 7 days
R7	Has_scope Arg1:T10 Arg2:T14	
T15	Condition 371 405	Central nervous system involvement
T16	Condition 408 417	Infection
T17	Procedure 428 455	systemic antibiotic therapy
T18	Qualifier 459 464	other
T19	Qualifier 465 472	serious
T20	Condition 473 482	infection
T21	Temporal 483 521	within 14 days before study enrollment
R8	Has_temporal Arg1:T20 Arg2:T21	
R9	Has_qualifier Arg1:T20 Arg2:T19	
R10	Has_qualifier Arg1:T20 Arg2:T18	
R11	AND Arg1:T16 Arg2:T17	
*	OR T16 T20
T22	Condition 557 582	cardiovascular conditions
T23	Qualifier 594 606	uncontrolled
T24	Condition 607 619	hypertension
T25	Qualifier 621 633	uncontrolled
T26	Condition 634 653	cardiac arrhythmias
T27	Qualifier 655 666	symptomatic
T28	Condition 667 691	congestive heart failure
T29	Condition 693 708	unstable angina
T30	Condition 713 734	myocardial infarction
T31	Temporal 735 759	within the past 6 months
R12	Has_temporal Arg1:T30 Arg2:T31	
R13	Has_qualifier Arg1:T24 Arg2:T23	
R14	Has_qualifier Arg1:T26 Arg2:T25	
R15	Has_qualifier Arg1:T28 Arg2:T27	
*	OR T24 T26 T30 T29 T28
T32	Qualifier 544 556	uncontrolled
T33	Temporal 536 543	current
R16	Has_qualifier Arg1:T22 Arg2:T32	
R17	Has_temporal Arg1:T22 Arg2:T33	
T34	Scope 594 759	uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months
T35	Scope 536 582	current uncontrolled cardiovascular conditions
R18	Subsumes Arg1:T35 Arg2:T34	
T36	Procedure 762 780	Systemic treatment
T37	Temporal 782 830	within 14 days before the first dose of ixazomib
T38	Reference_point 804 830	the first dose of ixazomib
T39	Drug 822 830	ixazomib
R19	Has_index Arg1:T37 Arg2:T38	
R20	multi Arg1:T38 Arg2:T39	
R21	Has_temporal Arg1:T36 Arg2:T37	
T40	Drug 837 879	strong cytochrome P450 3A (CYP3A) inducers
T41	Drug 881 889	rifampin
T42	Drug 891 902	rifapentine
T43	Drug 904 913	rifabutin
T44	Drug 915 928	carbamazepine
T45	Drug 930 939	phenytoin
T46	Drug 941 954	phenobarbital
*	OR T41 T42 T43 T44 T45 T46
T47	Scope 881 954	rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital
R22	Subsumes Arg1:T40 Arg2:T47	
T48	Drug 967 980	Ginkgo biloba
T49	Drug 984 999	St. John's wort
*	OR T48 T49 T40
T50	Scope 837 999	strong cytochrome P450 3A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort
R23	Has_scope Arg1:T36 Arg2:T50	
T51	Qualifier 1013 1019	active
T52	Temporal 1002 1009	Ongoing
T53	Condition 1020 1038	systemic infection
T54	Qualifier 1040 1046	active
T55	Condition 1047 1058;1064 1079	hepatitis B virus infection
T56	Condition 1062 1079	C virus infection
*	OR T55 T56
T57	Scope 1047 1079	hepatitis B or C virus infection
R24	Has_qualifier Arg1:T57 Arg2:T54	
*	OR T51 T52
T58	Scope 1002 1019	Ongoing or active
R25	Has_scope Arg1:T53 Arg2:T58	
*	OR T53 T57 T59
T59	Measurement 1090 1118	human immunodeficiency virus
T60	Value 1119 1127	positive
R26	Has_value Arg1:T59 Arg2:T60	
T61	Condition 1163 1173	malignancy
T62	Temporal 1174 1212	within 2 years before study enrollment
T63	Temporal 1216 1226	previously
T64	Qualifier 1242 1249	another
T65	Condition 1250 1260	malignancy
R27	Has_qualifier Arg1:T65 Arg2:T64	
R28	Has_temporal Arg1:T61 Arg2:T62	
R29	Has_temporal Arg1:T65 Arg2:T63	
*	OR T61 T65
T66	Condition 1286 1302	residual disease
T67	Mood 1270 1285	any evidence of
R30	Has_mood Arg1:T66 Arg2:T67	
T68	Condition 1322 1346	non-melanoma skin cancer
T69	Condition 1350 1367	carcinoma in situ
T70	Qualifier 1371 1379	any type
R31	Has_qualifier Arg1:T69 Arg2:T70	
*	OR T68 T69
T71	Negation 1384 1396	not excluded
T72	Procedure 1420 1438	complete resection
A2	Optional T72
R32	Has_negation Arg1:T72 Arg2:T71	
T73	Scope 1322 1379	non-melanoma skin cancer or carcinoma in situ of any type
R33	AND Arg1:T73 Arg2:T72	
T74	Qualifier 1445 1482	greater than or equal to (>=) Grade 2
T75	Condition 1483 1504	peripheral neuropathy
R34	Has_qualifier Arg1:T75 Arg2:T74	
T76	Qualifier 1509 1516	Grade 1
T77	Condition 1522 1526	pain
T78	Scope 1509 1526	Grade 1 with pain
T79	Scope 1445 1504	greater than or equal to (>=) Grade 2 peripheral neuropathy
*	OR T79 T78
T80	Drug 1581 1583	PD
T81	Qualifier 1587 1605	first-line therapy
R35	Has_qualifier Arg1:T80 Arg2:T81	
T82	Competing_trial 1608 1661	Participation in other interventional clinical trials
T83	Temporal 1741 1782	within 30 days of the start of this trial
T84	Temporal 1787 1824	throughout the duration of this trial
T85	Reference_point 1759 1782	the start of this trial
R36	Has_index Arg1:T83 Arg2:T85	
T86	Reference_point 1798 1824	the duration of this trial
R37	Has_index Arg1:T84 Arg2:T86	
*	OR T83 T84
T87	Scope 1741 1824	within 30 days of the start of this trial and throughout the duration of this trial
R38	AND Arg1:T82 Arg2:T87	
